Getty ImagesNEW DELHI: Shares of Ltd. traded 4.48 per cent down in Thursday's trade at 02:06PM (IST). Around 218,748 shares changed hands on the counter.
The counter opened at Rs 668.0 and touched an intraday high and low of Rs 668.75 and Rs 634.0, respectively, in the session so far. Shares of the company of Aurobindo Pharma Ltd. quoted a 52-week high of Rs 1063.75 and a 52-week low of Rs 634.0.
As per BSE, the total market cap of the Aurobindo Pharma Ltd. stood at Rs 37309.64 crore at the time of writing this report.
Key Financials
The company reported consolidated sales of Rs 6038.5 crore for the quarter ended 30-Sep-2021, up 4.41 per cent from previous quarter's Rs 5783.29 crore and up 7.63 per cent from the year-ago quarter's Rs 6537.19 crore.
The net profit for latest quarter stood at Rs 696.99 crore, down 13.55 per cent from the corresponding quarter last year.
Shareholding pattern
As of 30-Sep-2021, DIIs held 9.28 per cent stake in the company, while foreign institutional investors held 21.71 per cent and the promoters 48.76 per cent.
Valuation ratio
According to BSE data, the stock traded at a price-to-earnings multiple of 7.15 and a price-to-book ratio of 2.36. A higher P/E ratio shows investors are willing to pay a higher price because of better future growth expectations. Price-to-book value indicates the inherent value of a company and is the measure of the price that investors are ready to pay even for no growth in the business.
Aurobindo Pharma Ltd. belongs to the Pharma - Indian industry.
The counter opened at Rs 668.0 and touched an intraday high and low of Rs 668.75 and Rs 634.0, respectively, in the session so far. Shares of the company of Aurobindo Pharma Ltd. quoted a 52-week high of Rs 1063.75 and a 52-week low of Rs 634.0.
As per BSE, the total market cap of the Aurobindo Pharma Ltd. stood at Rs 37309.64 crore at the time of writing this report.
Key Financials
The company reported consolidated sales of Rs 6038.5 crore for the quarter ended 30-Sep-2021, up 4.41 per cent from previous quarter's Rs 5783.29 crore and up 7.63 per cent from the year-ago quarter's Rs 6537.19 crore.
The net profit for latest quarter stood at Rs 696.99 crore, down 13.55 per cent from the corresponding quarter last year.
Shareholding pattern
As of 30-Sep-2021, DIIs held 9.28 per cent stake in the company, while foreign institutional investors held 21.71 per cent and the promoters 48.76 per cent.
Valuation ratio
According to BSE data, the stock traded at a price-to-earnings multiple of 7.15 and a price-to-book ratio of 2.36. A higher P/E ratio shows investors are willing to pay a higher price because of better future growth expectations. Price-to-book value indicates the inherent value of a company and is the measure of the price that investors are ready to pay even for no growth in the business.
Aurobindo Pharma Ltd. belongs to the Pharma - Indian industry.
Pick the best companies to invest
BECOME AN ETPRIME MEMBERRead More News on
(What's moving Sensex and Nifty Track latest market news, stock tips and expert advice on ETMarkets. Also, ETMarkets.com is now on Telegram. For fastest news alerts on financial markets, investment strategies and stocks alerts, subscribe to our Telegram feeds.)
Download The Economic Times News App to get Daily Market Updates & Live Business News.